Filing Flows

Filing Flows › Companies › Generate Biomedicines › Cash flow

Generate Biomedicines cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$58.9M in Q2 2026

Operating cash flow−$57.9M
Capital spending−$933K
Free cash flow−$58.9M

Analysis

In Q2 2026, Generate Biomedicines generated −$57.9M of operating cash flow and spent $933K on capital projects, leaving free cash flow of −$58.9M. That is $10.0M less than in Q2 2025 (−$48.9M).

Operating cash flow was −$57.9M against net income of −$67.3M. The largest differences: stock-based pay +$8.2M, deferred revenue −$6.3M, prepaid and other assets +$5.9M.

Free cash flow

Generate Biomedicines: free cash flow by quarterGenerate Biomedicines: free cash flow by quarter−$53.9MQ1 2025−$48.9MQ2 2025−$84.2MQ1 2026−$58.9MQ2 2026
Operating cash flow less capital spending.
Generate Biomedicines: operating cash flow against capital spendingGenerate Biomedicines: operating cash flow against capital spendingOperating cash flowCapital spending−$53.2M$751KQ1 2025−$48.8M$154KQ2 2025−$80.4M$3.8MQ1 2026−$57.9M$933KQ2 2026
Latest (Q2 2026): Operating cash flow −$57.9M, Capital spending $933K.

Where the cash came from and went

Generate Biomedicines: sources (+) and uses (−) of cash, Q2 2026Generate Biomedicines: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$57.9MOther investing$34.2MCash drawn (+) / kept (−)$25.2MNet borrowing (+) / repaid (−)−$993KCapital spending−$933KShares issued$414K

From profit to cash

Generate Biomedicines: net income to operating cash flow, Q2 2026Generate Biomedicines: net income to operating cash flow, Q2 2026Net income−$67.3MDepreciation & amortization$3.2MStock-based pay$8.2MPayables−$2.0MAccrued liabilities$4.2MDeferred revenue−$6.3MPrepaid and other assets$5.9MOperating cash flow−$57.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$57.9M−$933K−$993K$414K$25.2M−$58.9M
Q1 2026−$80.4M−$3.8M−$1.1M$373M−$38.6M−$84.2M
Q2 2025−$48.8M−$154K−$2.4M$153K$66.1M−$48.9M
Q1 2025−$53.2M−$751K−$2.6M$22.5M−$42.9M−$53.9M

Generate Biomedicines: income statement and cash flow

Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year). The chart follows the revenue to costs, profit and cash.

Generate Biomedicines: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.